The following studies were recently activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office.
Click the study links below to learn details regarding the study on clinicaltrials.gov. For more information or questions about a study, email email@example.com or call 312-355-5112.
Protocol Title: HCRN-BRE17-141: An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in Triple Positive Breast Cancers
PI: Oana Danciu, MD
Sponsor: Hoosier Cancer Research Network
Protocol Title: : INCAGN2385-203: A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1 Positive (CPS >/-1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
PI: Lawrence Feldman, MD
Sponsor: Incyte Corporation